MLL-AF9-transformed cells were also used to design and implement a sophisticated approach for the identification of novel agents suitable for targeting leukemia stem cells in the context of the stromal microenvironment, which is believed to play a key role in promoting the maintenance and expansion of this subpopulation of leukemic cells. The gene discussed is KMT2A; the disease is leukemia.